MedTrace Logo

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

NCT00958841 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2016-07-26

Study results available
· View outcomes & findings →

Summary

This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.

Conditions

  • Pancreatic Neoplasm
  • Pituitary Neoplasm
  • Nelson Syndrome
  • Ectopic ACTH Syndrome

Interventions

DRUG

pasireotide LAR

Investigational drug pasireotide LAR was supplied in vials with 20 mg or 40 mg powder and 2 mL vehicle was supplied in ampoules for reconstitution.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Canada
  • France
  • Germany
  • Italy
  • Mexico
  • Russia
  • Spain
  • Thailand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00958841 on ClinicalTrials.gov